相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
Alessandro Nepote et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Julia R. Dixon-Douglas et al.
CURRENT ONCOLOGY REPORTS (2022)
First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma
Sergio Jobim de Azevedo et al.
PIGMENT CELL & MELANOMA RESEARCH (2021)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma A Review
Reinhard Dummer et al.
JAMA ONCOLOGY (2020)
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Pier Francesco Ferrucci et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Optimal treatment strategy for metastatic melanoma patients harboringBRAF-V600mutations
Emilio Francesco Giunta et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid et al.
CLINICAL CANCER RESEARCH (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
Meredith S. Pelster et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Management of metastatic cutaneous melanoma: updates in clinical practice
Gustavo Schvartsman et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunological effects of BRAF plus MEK inhibition
Paolo A. Ascierto et al.
ONCOIMMUNOLOGY (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
Teresa Amaral et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin et al.
LANCET ONCOLOGY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Jennifer A. Wargo et al.
CANCER DISCOVERY (2014)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
分享论文
